Transient hair loss in patients with chronic spontaneous urticaria treated with omalizumab
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
M Noshela Ghazanfar, S F Thomsen
Summary: Omalizumab (anti-IgE) is used as add-on therapy for antihistamine refractory chronic urticaria patients. The most commonly reported adverse effects were headache, arthralgia, upper respiratory infections, fatigue, nausea and injection-site reactions. However, lately a few cases of hair loss have been reported. We describe a case of transient hair loss in a young female patient after initiating treatment with omalizumab. Despite this side effect, the patient continued with omalizumab treatment for 10 months with good effect.
|Tidsskrift||European Annals of Allergy and Clinical Immunology|
|Status||Udgivet - nov. 2017|